Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now later-stage tilt small index

Severe Asthma: later-stage trial registry

6 of 10 indexed Severe Asthma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Severe Asthma: 10 US clinical trials tracked, 6 recruiting.

Severe Asthma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Generate Biomedicines, running 2 of these trials.

Enrollment posture brief

Registry condition severe-asthma

OPEN 6 | RECR 60% | LATE 4 | EARLY 2 | RANK #1724 | SPON 2

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Severe Asthma (this)60%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Severe Asthma

Severe Asthma lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Severe Asthma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Severe Asthma is recruiting above its size-band peers.

    6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Severe Asthma research.

    Generate Biomedicines accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Severe Asthma enrolment sits around 436 participants.

    Median target enrolment is 436 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Severe Asthma splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 33Phase 41

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 3 786 participants

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

Generate Biomedicines

NCT07359846

RECRUITING Phase 3 786 participants

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

Generate Biomedicines

NCT07276724

RECRUITING Phase 2 436 participants

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Upstream Bio

NCT06966479

RECRUITING 50 participants

Phenotyping Asthma for Bronchial Thermoplasty

Massachusetts General Hospital

NCT03435237

RECRUITING 5 participants

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

Bastiaan Driehuys

NCT07139899

RECRUITING 5 participants

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma

University of Kansas Medical Center

NCT06985225

ACTIVE NOT RECRUITING 31,795 participants

Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System

San Diego State University

NCT06389058

ACTIVE NOT RECRUITING Phase 2 479 participants

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Upstream Bio

NCT06196879

ACTIVE NOT RECRUITING Phase 3 326 participants

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

AstraZeneca

NCT06473779

COMPLETED Phase 4 26 participants

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

University of Texas Southwestern Medical Center

NCT00621946

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 3
Phase 4 1

Named interventions

Most-linked intervention names on Severe Asthma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
GB-0895 Drug
2 trials
Recommendation for the diagnoses and treatment of Severe Asthma Other
1 trials
Verekitug (UPB-101) Drug
1 trials
Salbutamol Combination
1 trials
Mannitol Combination
1 trials
Albuterol/budesonide (AIRSUPRA®) Combination
1 trials
Budesonide/formoterol Combination
1 trials

US sites by state

Facility locations filed on Severe Asthma trials. A trial with sites in several states counts in each.

Florida 5 trials
California 5 trials
Texas 3 trials
Michigan 2 trials
Massachusetts 2 trials
Colorado 2 trials
Oklahoma 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Severe Asthma page

10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Severe Asthma condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.